Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study

Jamie L Fleet, Stephanie N Dixon, Paul John Kuwornu, Varun K Dev, Manuel Montero-Odasso, Jorge Burneo, Amit X Garg, Jamie L Fleet, Stephanie N Dixon, Paul John Kuwornu, Varun K Dev, Manuel Montero-Odasso, Jorge Burneo, Amit X Garg

Abstract

Gabapentin is an effective treatment for chronic neuropathic pain but may cause dizziness, drowsiness, and confusion in some older adults. The goal of this study was to assess the association between gabapentin dosing and adverse outcomes by obtaining estimates of the 30-day risk of hospitalization with altered mental status and mortality in older adults (mean age 76 years) in Ontario, Canada initiated on high dose (>600 mg/day; n = 34,159) compared to low dose (≤600 mg/day; n = 76,025) oral gabapentin in routine outpatient care. A population-based, retrospective cohort study assessing new gabapentin use between 2002 to 2014 was conducted. The primary outcome was 30-day hospitalization with an urgent head computed tomography (CT) scan in the absence of evidence of stroke (a proxy for altered mental status). The secondary outcome was 30-day all-cause mortality. The baseline characteristics measured in the two dose groups were similar. Initiation of a high versus low dose of gabapentin was associated with a higher risk of hospitalization with head CT scan (1.27% vs. 1.06%, absolute risk difference 0.21%, adjusted relative risk 1.29 [95% CI 1.14 to 1.46], number needed to treat 477) but not a statistically significant higher risk of mortality (1.25% vs. 1.16%, absolute risk difference of 0.09%, adjusted relative risk of 1.01 [95% CI 0.89 to 1.14]). Overall, the risk of being hospitalized with altered mental status after initiating gabapentin remains low, but may be reduced through the judicious use of gabapentin, use of the lowest dose to control pain, and vigilance for early signs of altered mental status.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Miller A, Price G. Gabapentin toxicity in renal failure: The importance of dose adjustment. Pain Med. 2009;10(1):190–2. doi:
    1. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane database Syst Rev. 2014;4:CD007938.
    1. Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. J Manag Care Pharm [Internet]. 2002;8(4):266–71. Available from: doi:
    1. Medscape. Neurontin (gabapentin) [Internet]. 2013 [cited 2015 Jan 22]. Available from:
    1. Post TW, editor. Gabapentin Drug Information. In: UpToDate [Internet]. Waltham MA; 2016. Available from:
    1. Parke-Davis. Gabapentin Prescribing Information [Internet]. Division of Pfizer Inc, NY, NY: 2015. [cited 2016 Jan 22]. Available from:
    1. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215–24.
    1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Control Trial. JAMA. American Medical Association; 1998. December 2;280(21):1831
    1. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry [Internet]. BMJ Group; 1999. February [cited 2017 Feb 8];66(2):251–2. Available from:
    1. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994. August;56(2):154–9.
    1. Zand L, McKian KP, Qian Q. Gabapentin Toxicity in Patients with Chronic Kidney Disease: A Preventable Cause of Morbidity. Am J Med. 2010;123(4):367–73. doi:
    1. Statistics Canada. CANSIM—051–0001—Estimates of population, by age group and sex for July 1, Canada, provinces and territories [Internet]. 2016 [cited 2017 Jan 22]. Available from:
    1. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies Vol. 147, Annals of Internal Medicine; 2007. p. 573–7.
    1. Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67–71.
    1. Spaia S, Tersi M, Sidiropoulou M, Askepidis N, Pazarloglou M, Iliadi V. Management of neuropathic pain in dialysis patients: An effective approach with gabapentin. Dial Transplantation 38 ()(pp 368–373), 2009Date Publ Sept 2009. 2009;(9):368–73.
    1. Wong MO, Eldon MA, Keane WF, Türck D, Bockbrader HN, Underwood BA, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol. 1995. June;35(6):622–6.
    1. Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, et al. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. BMC Nephrol. 2013;14(81):1–8.
    1. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials Vol. 25, Clinical Therapeutics; 2003. p. 81–104.
    1. Dogukan A, Aygen B, Berilgen MS, Dag S, Bektas S, Gunal AI˙. Gabapentin-induced coma in a patient with renal failure. Hemodial Int. 2006;10:168–9. doi:
    1. Williams J, Young W. A summary of studies on the quality of health care administrative databases in Canada In: Goel V, Williams JI, Anderson GM, Blacksterin-Hirsch P, Fooks C, Naylor CD, editors. Patterns of Health Care in Ontario: The ICES Practice Atlas. Ottawa: Canadian Medical Association; 1996. p. 339–45.
    1. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: A population-based comparison. J Am Coll Cardiol. 1996;27(6):1335–42.
    1. Wodchis WP, Arthurs E, Khan AI, Gandhi S, MacKinnon M, Sussman J. Cost trajectories for cancer patients. Curr Oncol. 2016;23:S64–75. doi:
    1. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Commun Stat—Simul Comput. 2009;38(6):1228–34.
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
    1. Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557–66.
    1. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12(1):56–8.
    1. Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management. Anaesthesia. 2002. May;57(5):451–62.
    1. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: A multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678–82.
    1. Parsons B, Tive L, Huang S. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother. 2004;2(3):157–62. doi:
    1. Dev V, Dixon S, Fleet J, Gandhi S, Gomes T, Harel Z, et al. Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study. BMC Nephrol. 2014;
    1. Tawadrous D, Dixon S, Shariff SZ, Fleet J, Gandhi S, Jain AK, et al. Altered mental status in older adults with histamine2-receptor antagonists: A population-based study. Eur J Intern Med. 2014

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit